Sarah Matthews, a spokesperson for the British Liver Trust was responding to a ruling from the National Insititute for Health and Clinical Excellence that Nexavar was too expensive to be made available to liver cancer patients, which may include alert bracelet wearers, on the NHS.
She argued that those with the disease regularly faced 'stigma and discrimination' and felt the decision is another disadvantage to them.
The spokesperson suggested that it leaves sufferers 'with no treatment options and a very short life expectancy'.
According to the government body, Nexavar could increase survival by just less than three months at a cost of around £27,000 per patient and therefore could not be justified.
Ms Matthews commented that it is a shame the institute was unable to reach an agreement with drug companies that routinely provide the medication in other parts of the world.
She argued that those with the disease regularly faced 'stigma and discrimination' and felt the decision is another disadvantage to them.
The spokesperson suggested that it leaves sufferers 'with no treatment options and a very short life expectancy'.
According to the government body, Nexavar could increase survival by just less than three months at a cost of around £27,000 per patient and therefore could not be justified.
Ms Matthews commented that it is a shame the institute was unable to reach an agreement with drug companies that routinely provide the medication in other parts of the world.
0 comments:
Post a Comment